|
|
News Breaks | | | | August 30, 2012 | | 10:18 EDT |  | ONXX, BAYRY | Onyx says Bayer submitted NDA for regorafenib for treatment of GIST
Bayer HealthCare (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that Bayer HealthCare has submitted a New Drug Application to the U.S. Food and Drug Administration for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors, or GIST, in patients whose disease has progressed despite prior treatment. Regorafenib is a Bayer compound developed by Bayer. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology. Bayer and Onyx will jointly promote regorafenib in the United States. | |
|
News For ONXX;BAYRY From The Last 14 Days Check below for free stories on ONXX;BAYRY the last two weeks. |
|
|
| May 24, 2013 | | 06:05 EDT |  | BAYRY | FDA targets IPhone urinalysis app, Bloomberg reports
 Subscribe for More Information | | | May 23, 2013 | | 06:05 EDT |  | BAYRY | Bayer initiated with an Equal Weight at Morgan Stanley
| | | May 21, 2013 | | 13:36 EDT |  | ONXX | Onyx Pharmaceuticals mentioned cautiously at BofA/Merrill
Subscribe for More Information | | | May 20, 2013 | | 17:20 EDT | | BAYRY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information | | | 07:28 EDT |  | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information | | | May 17, 2013 | | 06:33 EDT | | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information | | | May 15, 2013 | | 11:43 EDT | | BAYRY | Bayer announces FDA approval for Xofigo as CRPC treatment
Subscribe for More Information | |
|
|
|
|
|
|
